CTD HOLDINGS, INC. (OTCMKTS:CTDH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 7, 2017, CTD Holdings, Inc. (the “Company”) and N. Scott Fine, the Company’s Chief Executive Officer, entered into an Amendment to Mr. Fine’s Employment Agreement extending the initial term thereof to September 14, 2020.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit 10.1 |
Amendment to Employment Agreement between the Company and N. Scott Fine, dated as of November 7, 2017. |
CTD HOLDINGS INC ExhibitEX-10.1 2 ex_99855.htm EXHIBIT 10.1 ex_99855.htm Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into as of November 7,…To view the full exhibit click here
About CTD HOLDINGS, INC. (OTCMKTS:CTDH)
CTD Holdings, Inc. is a biotechnology company. The Company is focused on the use of cyclodextrins in drug development. The United States Food and Drugs Administration has accepted the Type II Drug Master File for its lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin), for filing, as a treatment for Neimann-Pick Type C disease (NPC). NPC is a fatal cholesterol metabolism disease found primarily in children and young adults. It also sells cyclodextrins and related products to the pharmaceutical, nutritional and other industries, primarily for use in diagnostics and specialty drugs. Its product lines include Trappsol, Aquaplex and AP-Flavor. The Trappsol product line includes basic cyclodextrins, and cyclodextrins with various chemical adducts resulting in over 100 various cyclodextrins. The Aquaplex product line includes various cyclodextrins combined with over 80 various ingredients. The AP-Flavor product lines are cyclodextrins that contain various food flavors.